Patents Issued in August 30, 2016
-
Patent number: 9427405Abstract: Novel liposomes are described which are capable of effectively binding beta amyloid peptide and are useful for the treatment, prevention and diagnosis of Alzheimer's disease. Binding ability is provided by the presence in the formulation of particular natural lipids identified by the Applicant. These comprise a constant component, made up of cholesterol and sphingomyelin, and an additional variable component, made up of selected lipids.Type: GrantFiled: June 10, 2009Date of Patent: August 30, 2016Assignee: Universita degli Studi de Milano-BicoccaInventors: Massimo Masserini, Francesca Re, Maria Silvia Sesana
-
Patent number: 9427406Abstract: A substantially monodisperse assemblage of particles 10 having interconnected pores 20 and a core 30 with at least one shell 40, 60 disposed about the core 30 as well as a method for their synthesis is disclosed.Type: GrantFiled: October 11, 2014Date of Patent: August 30, 2016Assignee: Nautilus Capital CorporationInventors: Andrey Gavryushin, Johannes Kobler, Juergen Sauer
-
Patent number: 9427407Abstract: Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.Type: GrantFiled: June 24, 2015Date of Patent: August 30, 2016Assignee: LOCL PHARMA, INC.Inventor: Paul Bosse
-
Patent number: 9427408Abstract: The present invention provides compositions for encapsulation of biomaterials in a silica-matrix. The present invention also provides methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials. In one embodiment, the present invention provides a method of encapsulating mammalian cells in a silica-matrix while maintaining metabolic activity. In another embodiment, the present invention provides a method of purifying cancer cells using a silica-matrix.Type: GrantFiled: November 7, 2012Date of Patent: August 30, 2016Inventors: Eduardo Reategui, Lisa Kasinkas, Alptekin Aksan
-
Patent number: 9427409Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.Type: GrantFiled: February 5, 2015Date of Patent: August 30, 2016Assignee: Sequential Medicine LimitedInventor: Lan Bo Chen
-
Patent number: 9427410Abstract: A method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion. The droplet or emulsion so created is an activatable phase change agent that is stable at room temperature and pressure.Type: GrantFiled: October 11, 2011Date of Patent: August 30, 2016Assignees: The University of North Carolina at Chapel Hill, The Arizona Board of Regents on Behalf of The University of Arizona, The Regents of the University of ColoradoInventors: Paul A. Dayton, Paul S. Sheeran, Terry O. Matsunaga, Mark A. Borden
-
Patent number: 9427411Abstract: The present invention relates to an antimicrobial topical composition and process for making such composition. The composition comprises of ionic silver, silver nanoparticles, and oxygen, combined within a gel medium and applied topically. The composition optimizes the ionic silver and silver nanoparticle ratio providing for sufficient ionic silver to be delivered as an immediate antimicrobial agent, and sufficient nanoparticle silver to provide time release for conversion to silver ions for continuing antimicrobial effectiveness.Type: GrantFiled: August 12, 2014Date of Patent: August 30, 2016Inventor: JoAnna M. Esty
-
Patent number: 9427412Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.Type: GrantFiled: February 3, 2016Date of Patent: August 30, 2016Assignee: Cynapsus Therapeutics, Inc.Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
-
Patent number: 9427413Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.Type: GrantFiled: June 25, 2010Date of Patent: August 30, 2016Assignee: OncoImmune, Inc.Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
-
Patent number: 9427414Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.Type: GrantFiled: January 7, 2016Date of Patent: August 30, 2016Assignee: LAND O'LAKES, INC.Inventor: Cindie M. Luhman
-
Patent number: 9427415Abstract: Compounds and methods for modifying sensory perception associated with transient sensory receptors TRPA1, TRPV1, and TRPA1V1. A method for screening compounds for modulation of TRPA1, TRPV1, and/or TRPA1V1. Compositions comprising TRPA1V1 agonists or antagonists, for modifying sensory perception of the compositions.Type: GrantFiled: March 24, 2015Date of Patent: August 30, 2016Assignee: The Procter & Gamble CompanyInventors: Koti Tatachar Sreekrishna, Yakang Lin
-
Patent number: 9427416Abstract: The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.Type: GrantFiled: June 29, 2012Date of Patent: August 30, 2016Assignee: Wyeth LLCInventors: Gary Robert Agisim, Richard John Kenny, Miron Gerard Still, Ellen Bland Gilliam, Helen Elizabeth Taylor
-
Patent number: 9427417Abstract: A process for reducing bacterial colonization in or around the area of a wound includes applying to the area a gel that includes at least one PEG and an aqueous composition which has a pH of from 2 to 4, a total solute concentration of from 1.8 to 4.0 Osm/L, and from 0.9 to 1.7 g/L of at least one cationic surfactant. The aqueous composition can include a buffer system that includes an organic acid and a salt of an organic acid. The gel is effective even when free of materials having antimicrobial properties other than those provided by the aqueous composition, such as sporicides, antifungals and antibiotics.Type: GrantFiled: March 19, 2016Date of Patent: August 30, 2016Assignee: Next Science, LLCInventor: Matthew Franco Myntti
-
Patent number: 9427418Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.Type: GrantFiled: August 23, 2011Date of Patent: August 30, 2016Assignee: GTX, INC.Inventors: James T. Dalton, Mitchell S. Steiner, Ronald A. Morton
-
Patent number: 9427419Abstract: The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.Type: GrantFiled: September 11, 2006Date of Patent: August 30, 2016Assignee: Abela Pharmaceuticals, Inc.Inventor: Jack De La Torre
-
Patent number: 9427420Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: GrantFiled: June 5, 2014Date of Patent: August 30, 2016Assignee: Synchroneuron, Inc.Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
-
Patent number: 9427421Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.Type: GrantFiled: July 15, 2015Date of Patent: August 30, 2016Assignee: ALPEX PHARMA S.A.Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz S. Ardalan
-
Patent number: 9427422Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.Type: GrantFiled: October 21, 2014Date of Patent: August 30, 2016Assignee: Infirst Healthcare LimitedInventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
-
Patent number: 9427423Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.Type: GrantFiled: March 10, 2009Date of Patent: August 30, 2016Assignee: ATRIUM MEDICAL CORPORATIONInventors: Thomas M. Swanick, Joseph Ferraro, Lisa Rogers, Paul Martakos
-
Patent number: 9427424Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.Type: GrantFiled: June 9, 2014Date of Patent: August 30, 2016Assignee: Naturewise Biotech & Medicals CorporationInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jung Chen, Wei-Jan Huang, Li-Ling Chi
-
Patent number: 9427425Abstract: The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal ?,?-unsaturated-?-methyl-?-lactone moiety derived from Annona squamosa or their compositions for prevention, treatment, inhibition or controlling inflammation and immune related diseases or disorders mediated through cytokines/chemokines or other biomarkers. The disclosure further discloses said Annona squamosa derived acetogenin(s), extract(s)/fraction(s) or their compositions for prevention, treatment, inhibition or controlling metabolic diseases/disorders.Type: GrantFiled: April 18, 2012Date of Patent: August 30, 2016Assignee: LAILA NUTRACEUTICALSInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Krishanu Sengupta, Kiran Bhupathiraju
-
Patent number: 9427426Abstract: Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol. Indication of use of erdosteine as prophylaxis for intoxications. Erdosteine can be administered per os or intravenous, using a solution obtained with sodium hydrogen carbonate and bidistilled water.Type: GrantFiled: August 13, 2009Date of Patent: August 30, 2016Assignee: RAFIFARM S.R.L.Inventors: Marco Peretto, Cristina Sarbulescu, Victor Voicu
-
Patent number: 9427427Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.Type: GrantFiled: January 21, 2014Date of Patent: August 30, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
-
Patent number: 9427428Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R? are, each independently, —CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.Type: GrantFiled: November 3, 2010Date of Patent: August 30, 2016Assignee: Janssen Sciences Ireland UCInventors: Koen Vandyck, Stefaan Julien Last, Ioannis Nicolaos Houpis, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 9427429Abstract: The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.Type: GrantFiled: February 28, 2011Date of Patent: August 30, 2016Assignee: Tau Therapeutics LLCInventor: Lloyd S. Gray
-
Patent number: 9427430Abstract: A compression therapy apparatus and a method for manufacturing and applying compression with the same may include a bandage and a tension indicator coupled to the bandage. A tension indicator may include a film having layers of liquid crystal droplets deposited on a polymer matrix. The tension indicator can be adapted to color shift under tension between the first end and the second end of the bandage.Type: GrantFiled: March 12, 2014Date of Patent: August 30, 2016Assignee: KCI Licensing, Inc.Inventors: Benjamin Stokes, Timothy Mark Robinson
-
Patent number: 9427431Abstract: The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.Type: GrantFiled: February 1, 2012Date of Patent: August 30, 2016Assignee: Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Michael K. Cooper, Jefferey A. Porter
-
Patent number: 9427432Abstract: Pharmaceutical compositions comprising berberine for treatment of skin disorders and methods of use thereof.Type: GrantFiled: December 19, 2014Date of Patent: August 30, 2016Assignee: TWi Biotechnology, Inc.Inventors: Pao-Li Wang, Way-Yu Lin, Chen-Mao Lin, Po-Yuan Tseng
-
Patent number: 9427433Abstract: Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided. These involve compositions that inhibit expression of interferon-gamma (IFN-?) or a downstream IFN-?-stimulated gene, which is preferably a macrolide immunosuppressant compound.Type: GrantFiled: May 31, 2012Date of Patent: August 30, 2016Assignee: Queen's University at KingstonInventors: Ahmad J. H. Albaghdadi, Frederick W. K. Kan
-
Patent number: 9427434Abstract: The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.Type: GrantFiled: July 10, 2008Date of Patent: August 30, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Hiroto Bando, Yoshihiro Omachi, Kenichiro Kiyoshima
-
Patent number: 9427435Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.Type: GrantFiled: September 22, 2014Date of Patent: August 30, 2016Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.Inventors: Kiichiro Nabeta, Toru Hibi
-
Patent number: 9427436Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.Type: GrantFiled: April 25, 2016Date of Patent: August 30, 2016Assignee: PharnextInventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
-
Patent number: 9427437Abstract: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.Type: GrantFiled: February 14, 2013Date of Patent: August 30, 2016Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Joseph A. Abboud, Louis J. Soslowsky
-
Patent number: 9427438Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.Type: GrantFiled: September 15, 2015Date of Patent: August 30, 2016Assignee: EIP Pharma, LLCInventor: John Jahangir Alam
-
Patent number: 9427439Abstract: The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.Type: GrantFiled: October 26, 2015Date of Patent: August 30, 2016Assignee: EIP Pharma, LLCInventor: John Jahangir Alam
-
Patent number: 9427440Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.Type: GrantFiled: March 15, 2013Date of Patent: August 30, 2016Assignee: Janssen Sciences Ireland UCInventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
-
Patent number: 9427441Abstract: Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.Type: GrantFiled: February 19, 2015Date of Patent: August 30, 2016Assignee: Indiana University Research and Technology CorporationInventor: Yang Sun
-
Patent number: 9427442Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.Type: GrantFiled: September 20, 2013Date of Patent: August 30, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Yufen Zhao, Ashvinikumar V. Gavai, Patrice Gill, Soong-Hoon Kim, Brian E. Fink, Libing Chen, Mark G. Saulnier, Wen-Ching Han
-
Patent number: 9427443Abstract: A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a bugger, excluding phosphate buffer pH 7.0, 0.1 M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0.Type: GrantFiled: July 8, 2014Date of Patent: August 30, 2016Assignee: Jurox Pty. Ltd.Inventors: Peter John Kieran, Kai Kin Lau, Barry Edward Patten
-
Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages
Patent number: 9427444Abstract: This invention relates to biology and medicine and in particular it can be used in medicine for preparation of pharmaceutical composition that can accelerate wound healing by means of directed transport of biologically active substances (bioactive compounds) to the mitochondria, using hydrogen electrochemical potential in mitochondria. Besides, this invention relates to a certain method of influencing on the organism by means of said directed transport of required biologically active substances.Type: GrantFiled: January 29, 2007Date of Patent: August 30, 2016Assignee: MITOTECH SAInventors: Vladimir P. Skulachev, Maxim V. Skulachev -
Patent number: 9427445Abstract: The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.Type: GrantFiled: June 22, 2012Date of Patent: August 30, 2016Assignee: N.V. NutriciaInventors: Johannes Wilhelmus Christina Sijben, Martine Sandra Alles
-
Patent number: 9427446Abstract: The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.Type: GrantFiled: October 21, 2013Date of Patent: August 30, 2016Assignee: EPIFARMA S.R.L.Inventors: Giuseppe Irianni, Cristina Macelloni, Luca Teseschi
-
Patent number: 9427447Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.Type: GrantFiled: September 10, 2014Date of Patent: August 30, 2016Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and DevelopmentInventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
-
Patent number: 9427448Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: GrantFiled: March 9, 2013Date of Patent: August 30, 2016Assignee: The Medicines CompanyInventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
-
Patent number: 9427449Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.Type: GrantFiled: June 6, 2011Date of Patent: August 30, 2016Assignee: ECONUGENICS, INC.Inventor: Isaac Eliaz
-
Patent number: 9427450Abstract: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.Type: GrantFiled: January 31, 2013Date of Patent: August 30, 2016Assignee: XON Cells, Inc.Inventors: Thomas Ichim, Vladimir Bogin
-
Patent number: 9427452Abstract: A method for preparing fermentation broth of fruits and vegetables includes steps of mixing fruits, vegetables, bacteria liquid of Lactobacillus acidophilus, bacteria liquid of Bifidobactreium longum, bacteria liquid of Lactobacillus delbrueckii subsp. bulgaricus, and bacteria liquid of Streptococcus thermophilus, and processing fermentation to obtain the fermentation broth of fruits and vegetables. A fermenting course of the method could be controlled, and a fermenting period is reduced to 15 days.Type: GrantFiled: July 20, 2013Date of Patent: August 30, 2016Assignee: Jilin Zixin Pharmaceutical Research Institution LLC.Inventors: Dejun Sun, Jinlong Yin, Miaonan Sun, Yizhuo Zhao, Chunsheng Guo, Yanhui Gao, Xue Li
-
Patent number: 9427453Abstract: In one embodiment, a method is provided for lowering C-reactive protein levels in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce C-reactive protein levels in the mammal. Other embodiments include, among other things, lowering leptin levels, increasing adiponectin levels, reducing body weight, decreasing LDL and total cholesterol levels, increasing fat loss, and reducing waist size in a mammal using administering a composition containing an effective amount of Irvingia gabonensis.Type: GrantFiled: April 1, 2014Date of Patent: August 30, 2016Inventor: Julius Enyoug Oben
-
Patent number: 9427454Abstract: A method of making liquid olive leaf extract that includes the mixing ground olive leaf, water, and an acid in a container. Once mixed heating the mixture a predetermined temperature for approximately four hours. Next raising the pH to approximately 4.0 and then adding a predetermined amount of cellulase and invertase to the mixture. Then the mixture is mixed for a predetermined period of time. After mixing, sediment is remove from the mixture and the pH is adjusted to approximately 3.0. The mixture is then reduced to a concentrate.Type: GrantFiled: February 26, 2014Date of Patent: August 30, 2016Inventor: Robert den Hoed
-
Patent number: 9427455Abstract: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.Type: GrantFiled: April 15, 2009Date of Patent: August 30, 2016Assignee: CLL PHARMAInventors: Jamal Temsamani, Claude Laruelle